ACD856 (NeuroRestore) is a revolutionary molecule: a positive allosteric modulator (PAM) of Trk receptors. No other known synthetic or natural molecule does this.
It is a neurogenesis promoter applicable to neurodegenerative diseases (Alzheimer's, etc.), brain injuries (stroke, etc.), and major depressive disorder (MDD).
ALZECURE PHARMA is behind the molecule, which is expected to enter phase 2A clinical trials this year.
The company's current market capitalization is only $17 million.
They are also working on ACD857.
----------------
COMPETITION
-The psychedelic industry, limited by the narcotic nature of these molecules.
-ALTO Neuroscience, behind NSI-189, a neurogenesis promoter with an unknown mechanism of action (MoA). This company is currently valued at $750 million.
(ACD856 works better according to anecdotal reviews on Reddit)
It is a neurogenesis promoter applicable to neurodegenerative diseases (Alzheimer's, etc.), brain injuries (stroke, etc.), and major depressive disorder (MDD).
ALZECURE PHARMA is behind the molecule, which is expected to enter phase 2A clinical trials this year.
The company's current market capitalization is only $17 million.
They are also working on ACD857.
----------------
COMPETITION
-The psychedelic industry, limited by the narcotic nature of these molecules.
-ALTO Neuroscience, behind NSI-189, a neurogenesis promoter with an unknown mechanism of action (MoA). This company is currently valued at $750 million.
(ACD856 works better according to anecdotal reviews on Reddit)
액티브 트레이드
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.